Wegovy Tablets Vs Injections

If you have been struggling with your weight for years and feel like nothing has worked, you are not alone — and in 2026, there is now more clinical support available in the UK than ever before. Wegovy tablets represent one of the most talked-about developments in weight management medicine, offering a new approach for adults who meet the clinical criteria for prescription weight loss treatment. Whether you have heard about it from a friend, seen it in the news, or been told about it by a healthcare professional, this guide will walk you through everything you need to know — clearly, honestly, and without the jargon.

Quick Summary

Wegovy is a semaglutide-based prescription weight loss treatment that works by mimicking a natural gut hormone to reduce appetite and support meaningful, sustained weight loss. It is approved in the UK and prescribed to adults with a BMI of 30 or above, or 27 and above with at least one weight-related health condition.

• Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces hunger signals in the brain
• Clinical trials show patients can lose up to 15% of their body weight over 68 weeks
• Treatment follows a structured dose escalation schedule to minimise side effects
• It is available in the UK via private prescription and select NHS pathways
• Lifestyle changes including diet and exercise are essential alongside treatment

Table of Contents

1. What Are Wegovy Tablets and How Do They Work?
2. Who Qualifies for Wegovy Tablets in the UK?
3. Wegovy Dose Escalation Schedule Explained
4. Common and Serious Side Effects to Know About
5. Wegovy Tablets vs Other Weight Loss Options
6. How to Get Started Safely in the UK
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. FAQs

What Are Wegovy Tablets and How Do They Work?

Wegovy is the brand name for semaglutide, a medication originally developed to treat type 2 diabetes. At higher doses, it was found to be remarkably effective for weight management, and it was subsequently licensed specifically for this purpose. Wegovy tablets — or more accurately, Wegovy injections that are self-administered once weekly — work by mimicking the effects of a naturally occurring gut hormone called glucagon-like peptide-1, or GLP-1. This hormone plays a key role in regulating appetite, food intake, and blood sugar levels. When you use Wegovy tablets, the semaglutide binds to GLP-1 receptors in the brain, particularly in areas responsible for hunger and reward. The result is a significant reduction in appetite, a feeling of fullness with smaller portions, and a reduced desire to eat between meals.

What makes this mechanism so clinically powerful is that it addresses one of the root biological causes of obesity — not just willpower or lifestyle choices. Many people living with obesity have hormonal and neurological factors that make it far harder for them to feel satisfied after eating. This is not a character flaw; it is physiology. Wegovy tablets help correct that imbalance. The medication also slows gastric emptying, meaning food stays in the stomach longer, contributing further to satiety. In large clinical trials, participants lost an average of 14.9% of their body weight over 68 weeks, which is a clinically meaningful result that goes far beyond what most lifestyle interventions alone can achieve.

• Semaglutide mimics the GLP-1 gut hormone to suppress appetite
• Slows gastric emptying, helping you feel fuller for longer
• Acts on brain receptors to reduce food cravings and reward-driven eating
• Does not cause sedation or stimulant effects unlike older weight loss drugs
• Addresses the biological drivers of obesity rather than relying on willpower alone

Who Qualifies for Wegovy Tablets in the UK?

Not everyone can access Wegovy tablets, and understanding the eligibility criteria is an important first step. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy for adults aged 18 and over who have a body mass index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² or above if they also have at least one weight-related comorbidity. Qualifying comorbidities include conditions such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, and cardiovascular disease. The treatment is intended to be used alongside a reduced-calorie diet and increased physical activity, rather than as a standalone solution.

There are also a number of contraindications to be aware of. Wegovy is not suitable for individuals with a personal or family history of medullary thyroid carcinoma (a rare type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2. It is also contraindicated during pregnancy and breastfeeding. People with a history of pancreatitis or severe gastrointestinal disease may not be suitable candidates either. A thorough medical consultation is therefore essential before starting treatment. In the UK's NHS setting, access has been phased, so many people are currently accessing it through private channels. If you are considering Mounjaro weight loss injections as an alternative, that pathway is also available through qualified UK prescribers.

• BMI of 30 or above, or BMI of 27 with a qualifying health condition
• Must be 18 years of age or older
• Not suitable during pregnancy, breastfeeding, or with certain thyroid conditions
• A full medication review is required before a prescription is issued
• Should be combined with lifestyle changes for best outcomes

Wegovy Dose Escalation Schedule Explained

One of the most important aspects of Wegovy tablets that people often overlook is the structured dose escalation protocol. You do not start at the full therapeutic dose immediately. Instead, your dose is gradually increased over several months. This approach is designed specifically to reduce the risk and severity of gastrointestinal side effects, which are the most common complaint among new users. Starting low and going slow allows your body to adjust to the medication comfortably, which significantly improves long-term tolerability and adherence. The full escalation schedule typically takes around 16 to 20 weeks before reaching the maintenance dose of 2.4 mg per week.

During this period, many people find that appetite suppression begins well before they reach the maintenance dose, which can be encouraging. However, it is important not to rush the escalation or skip steps. If side effects at any dose level are severe, your prescriber may recommend staying at the current dose for an additional four weeks before moving up. If you have been looking at Orlos Orlistat 60mg weight loss aid as a comparison, it is worth noting that Wegovy works through an entirely different mechanism and generally produces greater weight loss results in clinical populations.

Week	Dose of Semaglutide	Purpose	Notes
Weeks 1–4	0.25 mg once weekly	Initial tolerability dose	Not a therapeutic weight loss dose; allows body to adjust
Weeks 5–8	0.5 mg once weekly	Gradual escalation	Some appetite suppression may begin at this stage
Weeks 9–12	1.0 mg once weekly	Continued escalation	Noticeable reduction in hunger for most patients
Weeks 13–16	1.7 mg once weekly	Pre-maintenance dose	Stronger appetite control; monitor for side effects
Week 17 onwards	2.4 mg once weekly	Maintenance therapeutic dose	Target dose for sustained weight loss; ongoing review recommended

It is also worth noting that Wegovy is administered as a subcutaneous injection rather than a tablet swallowed orally. The term "Wegovy tablets" is commonly used in search queries, but the product itself comes in a pre-filled pen device that delivers the medication just under the skin — much like an insulin pen. The injection sites rotate between the abdomen, thigh, and upper arm. Many patients find that after the first few administrations, the process becomes quick and straightforward.

Common and Serious Side Effects to Know About

Like all prescription medications, Wegovy tablets come with a side effect profile that you should understand before starting treatment. The most commonly reported side effects are gastrointestinal in nature, and they tend to be most pronounced during the dose escalation phase. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. For many people, these symptoms are mild to moderate and improve significantly once the body adapts — usually within the first four to eight weeks at each new dose level. Taking Wegovy tablets on a consistent day each week and avoiding high-fat or excessively large meals can help reduce nausea.

More serious side effects are less common but require immediate medical attention. These include symptoms of pancreatitis such as severe and persistent abdominal pain radiating to the back, signs of gallbladder problems including sudden upper-right abdominal pain, and any symptoms that might suggest an allergic reaction such as difficulty breathing, facial swelling, or a widespread rash. There have also been reports of a slight increase in heart rate in some patients, so those with pre-existing cardiovascular concerns should be monitored closely. Mental health changes, including new or worsening depression, have been reported with GLP-1 medications and should be discussed openly with your prescriber. If you experience any serious symptoms, seek urgent medical advice.

• Nausea is the most common side effect, especially in the first few weeks of each new dose
• Eating smaller, lower-fat meals can significantly reduce gastrointestinal discomfort
• Seek urgent help for severe abdominal pain, signs of pancreatitis, or allergic reactions
• Report any mood changes or new depressive symptoms to your prescriber promptly
• Most side effects are dose-dependent and improve as your body adjusts

Wegovy Tablets vs Other Weight Loss Options

With so many weight loss products and programmes available, it can be difficult to know how Wegovy tablets compare. One of the most common comparisons people make is between Wegovy and Mounjaro (tirzepatide), another injectable weight loss medication that targets both GLP-1 and GIP receptors. Early data suggests Mounjaro may produce slightly greater weight loss on average, but Wegovy has a longer track record and is well-established within UK prescribing guidelines. Both are prescription-only medications that require a full consultation and cannot be purchased over the counter. For those who are not yet eligible for prescription treatment or who prefer an over-the-counter option, products such as XLS Medical Weight Loss Plus tablets offer a different approach using plant-derived fibre technology to reduce dietary fat absorption, though weight loss outcomes are generally more modest.

Orlistat-based products, available both on prescription and over the counter, work by blocking the absorption of dietary fat in the gut. They are effective when used correctly but come with challenging side effects if you consume too much fat in your diet. Behavioural and psychological interventions such as cognitive behavioural therapy for weight management, calorie restriction programmes, and commercial diet plans can also support weight loss, but are far less effective than pharmacological treatment for people with clinically significant obesity. Wegovy tablets sit firmly at the top of the evidence hierarchy for non-surgical weight management in the UK as of 2026, particularly for those with obesity-related health conditions who have not responded adequately to lifestyle interventions alone. You might also consider XLS Medical Direct Fat Binder sachets as a complementary over-the-counter support option.

• Wegovy produces greater average weight loss than orlistat or over-the-counter supplements
• Mounjaro may offer marginally superior results but both require a full clinical assessment
• Over-the-counter options can support lifestyle changes but do not match prescription results
• Surgical options like bariatric surgery remain available for those with severe obesity
• A combined approach — medication, diet, and activity — consistently outperforms any single strategy

How to Get Started Safely in the UK

Starting Wegovy tablets safely in the UK requires going through a legitimate prescribing pathway. This means completing a thorough online or in-person medical consultation with a qualified prescriber who will review your medical history, current medications, BMI, and any relevant health conditions. At Cured Pharmacy, this process is handled by GPhC-registered prescribing pharmacists who can assess your suitability, issue a private prescription, and arrange discreet delivery directly to your home. The entire assessment process takes under three minutes and is reviewed by a UK-based clinical professional — not an automated algorithm.

Once you have your prescription and your first supply of Wegovy tablets, it is important to follow the injection schedule consistently. Choose a day of the week that suits your routine and stick to it — the same day each week regardless of meals or time of day. Store your pens in the refrigerator as directed and allow the pen to reach room temperature before injecting. Keep a note of your starting weight and measurements so you can track progress objectively, and schedule regular follow-up appointments with your prescriber to review your response to treatment and adjust the plan if needed. If nausea or other gastrointestinal symptoms are affecting your quality of life, do not simply stop the medication — speak to your prescriber, who may suggest slowing your dose escalation or providing additional symptom management support. For additional reading on thyroid health which can sometimes be relevant to weight gain, you can also explore Newfoundland thyroid testing to rule out underlying conditions.

• Always obtain Wegovy through a regulated UK prescriber — never from unverified online sources
• Complete a full medical consultation before your first prescription is issued
• Store pens in the fridge and allow them to warm before use to reduce injection discomfort
• Book regular follow-up reviews to monitor progress and manage side effects
• Pair your prescription with a realistic calorie-controlled diet and gradual increase in activity

Key Takeaways

• Wegovy tablets (semaglutide) are a MHRA-approved prescription weight loss treatment that reduce appetite by mimicking the GLP-1 gut hormone
• Clinical trials demonstrate an average weight loss of up to 15% of body weight over 68 weeks when combined with lifestyle changes
• The structured dose escalation from 0.25 mg to 2.4 mg weekly is essential for minimising gastrointestinal side effects
• Wegovy is only suitable for eligible adults and must be prescribed by a qualified UK healthcare professional — never self-medicate
• Long-term success with Wegovy depends on consistency, regular prescriber reviews, and sustainable dietary and lifestyle changes alongside treatment

When to Seek Professional Advice

There are several situations in which you should contact your prescriber or seek urgent medical advice without delay. If you experience severe or persistent abdominal pain, particularly pain that radiates to your back, this could indicate pancreatitis, which is a serious condition requiring immediate assessment. Sudden yellowing of the skin or eyes (jaundice) or severe upper-right abdominal pain may suggest gallbladder problems and warrants urgent evaluation. If you notice signs of an allergic reaction — including difficulty breathing, swelling of the face, lips, tongue, or throat — call 999 or go to your nearest accident and emergency department immediately.

You should also contact your prescriber if you experience rapid or irregular heartbeat, significant changes in mood or mental health, or if you develop any new or worsening symptoms that you are concerned about. If you are taking diabetes medications alongside Wegovy, particularly insulin or sulfonylureas, you may be at increased risk of hypoglycaemia (low blood sugar) and should discuss dose adjustments with your prescriber. Finally, if you become pregnant or are planning a pregnancy, stop Wegovy immediately and seek advice from your GP or obstetric team. This is not an exhaustive list — always err on the side of caution and speak to a healthcare professional if you are unsure about any symptom.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal Guidance TA875. NICE, 2023.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 2021. Published in The Lancet Diabetes & Endocrinology.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory approval of Wegovy (semaglutide). GOV.UK, 2023.

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets typically begin to reduce appetite within the first one to two weeks of starting treatment, though meaningful weight loss is usually noticed after four to eight weeks. Most clinical studies show significant results after twelve weeks of consistent use alongside a calorie-reduced diet and regular physical activity.

Is Wegovy safe for long-term use in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified UK prescriber. Clinical trials lasting up to two years have shown sustained weight loss with an acceptable safety profile. Regular check-ins with your prescriber are recommended to monitor progress, manage any side effects, and adjust your dose as needed.

Can you take Wegovy tablets with other medications?

Wegovy tablets can interact with certain medications, particularly those used to manage diabetes such as insulin or sulfonylureas, which may increase the risk of low blood sugar. Always disclose your full medication list to your prescriber before starting Wegovy tablets, as interactions with oral contraceptives and thyroid medications should also be carefully assessed.

What is the starting dose of Wegovy tablets in the UK?

The starting dose of Wegovy tablets in the UK is 0.25 mg of semaglutide once weekly for the first four weeks. The dose is then gradually increased every four weeks up to the target maintenance dose of 2.4 mg weekly, a structured escalation designed to reduce the likelihood of gastrointestinal side effects during treatment.